The theme of this proposal is to both enhance target discovery/confirmation in the projects and to translate such findings regarding potential targets including BH3 proteins/apoptosis machinery, ubiquitin ligases, and key transcription factors. Some or all of these targets will be tested as potentially useful therapeutic strategies by means of early phase clinical trials. Clinical Research Support Core resources are required to carry out these clinical trials and assays on human leukemia cells obtained both at diagnosis/relapse and during the course of therapeutic studies. The personnel in this core will closely interact with the biostatisticians in Core C for trial design, data quality assurance and analysis of results. This Core will be responsible for obtaining required diagnostic and post-treatment samples which will be stored in the tissue bank facility described in Biospecimen Core B after obtaining appropriate consent. Thus the overall Specific Aims of the clinical research support core are to: 1. Collect cells at diagnosis and relapse from patients with AML and higher-risk MDS for storage and annotation in Biospecimen Core B who will perform key biology-defining assays and provide cells to the projects for target development and validation 2. To conduct clinical trials (including obtaining material for ancillary studies) with agents derived from preclinical science in the projects To accomplish these aims we will: * Recruit and enroll eligible patients (including appropriate numbers of individuals across age, gender, ethnicity and racial groups) f o r t h e clinical trials in myeloid leukemias * Coordinate the operation of the clinical trials described in this application. Ensure that study parameters are followed;confirm eligibility for patient registration, treatment program adherence, HIPPA compliance, appropriate dose modification, collection of ancillary data and specimens, adverse event reporting, and toxicity/response assessment * Collect research specimens and distribute ancillary samples via the Biospecimen Core C sample acquisition, storage and distribution mechanism to investigators at the relevant laboratories in the Projects (in some cases straightforward assays may be carried out by Core D shortly after blast isolation if required) * Act as liaison with pharmaceutical companies, outside physicians and hospitals to coordinate the collection of research specimens and follow-up data * Provide central data management for collection and documentation of individual patient information

Public Health Relevance

The research carried out in this project will enable the development of less toxic and more specific therapies for patients with AML and high risk MDS. We plan to rapidly translate laboratory discoveries into useful therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17

Showing the most recent 10 out of 376 publications